Longitudinal Evaluation of Both Morphologic and Functional Changes in the Same Individuals with Alzheimers Disease
Hiroshi Matsuda, MD1,
Noriyuki Kitayama, MD2,3,
Takashi Ohnishi, MD1,
Takashi Asada, MD4,
Seigo Nakano, MD5,
Shigeki Sakamoto, MD1,
Etsuko Imabayashi, MD1 and
Asako Katoh, MD1
1 Department of Radiology, National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan
2 Department of Radiology, University of Washington Medical Center, Seattle, Washington
3 Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan
4 Department of Neuropsychiatry, Tsukuba University, Ibaraki, Japan
5 Department of Geriatric Medicine, National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan

View larger version (99K):
[in a new window]
|
FIGURE 1. SPM99 corrected for multiple comparisons (P = 0.05). Images show significantly lower (P = 0.001) gray matter volume in AD patients, in comparison with that in healthy volunteers, at baseline (A) and at 1-y (B) and 2-y (C) follow-up. Significant decrease is shown as colored areas superimposed on transaxial slices of standard MR images.
|
|

View larger version (102K):
[in a new window]
|
FIGURE 2. SPM99 corrected for multiple comparisons (P = 0.05). Images show significantly lower (P = 0.001) adjusted rCBF in relative flow distribution (normalization of global cerebral blood flow for each subject to 50 mL/100 g/min with proportional scaling) in AD patients, in comparison with that in healthy volunteers, at baseline (A) and at 1-y (B) and 2-y (C) follow-up. Significant decrease is shown as colored areas superimposed on transaxial slices of standard MR images.
|
|

View larger version (65K):
[in a new window]
|
FIGURE 3. SPM99 corrected for multiple comparisons (P = 0.05). Dual-color display of surface-rendered standard MR images from 8 viewpoints shows significantly lower (P = 0.001) gray matter volume (red) and rCBF (green) in AD patients, in comparison with those in healthy volunteers. Areas of overlap are indicated by yellow.
|
|
Copyright © 2002 by the Society of Nuclear Medicine.